WILLIAM M. SMITH, M.D. (ASSOCIATE); ANTHONY N. DAMATO, M.D.; NICHOLAS J. GALLUZZI, M.D., (ASSOCIATE); CLAUDE F. GARFIELD, M.D.; ERNEST G. HANOWELL, M.D., F.A.C.P.; WILLIAM H. STIMSON, M.D., F.A.C.P.; RICHARD H. THURM, M.D., F.A.C.P.; JOHN J. WALSH, M.D., F.A.C.P.; LOUIS BROMER, B.A.
The need for adequate clinical trial of therapeutic agents is particularly evident in the field of antihypertensive drugs. It is not possible for individual physicians to evaluate properly the plethora of agents available and recommended for use. The mounting evidence that early and effective therapy is beneficial lends urgency to the need to know which of, or in what combination, these agents are most efficacious and least toxic. Guidelines based on valid clinical trial must be established.
Many efforts have lacked validity due to insufficient numbers of cases, lack of appropriate controls, and failure to eliminate bias. The cooperative study
SMITH WM, DAMATO AN, GALLUZZI NJ, et al. The Evaluation of Antihypertensive Therapy Cooperative Clinical Trial Method: I. Double-blind Control Comparison of Chlorothiazide, Rauwolfia Serpentina, and Hydralazine. Ann Intern Med. 1964;61:829–846. doi: https://doi.org/10.7326/0003-4819-61-5-829
Download citation file:
Published: Ann Intern Med. 1964;61(5_Part_1):829-846.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use